需要治疗的早产儿视网膜病变的男女比例:一项系统综述与Meta分析
该系统综述与Meta分析检索2000至2022年PubMed、Embase和Web of Science数据库,纳入316项研究共31026例接受治疗的早产儿视网膜病变(ROP)患者。接受治疗的男性婴儿比例较高(55% [95% CI, 0.54%-0.55%]),研究间异质性低(I2=34%;P<.001)。38项研究报告筛查人群中男女分布(170053例;男性92612例[53%] vs 女性77441例[47%]),筛查男婴与女婴接受治疗的比值无显著差异(合并比值比1.04 [95% CI, 0.91-1.18];P=.67)。
要点
- 接受ROP治疗的男性婴儿比例较高(55% [95% CI, 0.54%-0.55%]),研究间异质性低(I2=34%;P<.001)。
- 筛查人群中男婴92612例(53%)与女婴77441例(47%)接受治疗的比值无显著差异(合并比值比1.04 [95% CI, 0.91-1.18];P=.67)。
- 作者认为男性ROP治疗更多可能与早产男婴已知的相对病理生理脆弱性及ROP筛查率差异有关,提示未来研究需关注并对男性新生儿进行更仔细的临床监测。
核心结论
- 接受ROP治疗的男性婴儿多于女性婴儿。
- 作者认为这可能与早产男婴已知的相对病理生理脆弱性以及ROP筛查率差异有关,即更多男婴符合筛查标准。
- 作者指出这些发现对未来研究有启示,并可能促使对男性新生儿进行更仔细的临床监测。
研究设计与样本
- 系统综述与Meta分析,检索PubMed、Embase和Web of Science数据库2000至2022年的文献。
- 纳入报告抗血管内皮生长因子、激光光凝和/或冷冻治疗ROP且报告治疗组性别分布的研究;排除病例报告、治疗患者少于10例的病例系列、系统综述、会议摘要、致编辑信、动物研究和非英文记录。
- 共纳入316项研究,累计31026例接受治疗的患者;38项研究报告筛查人群性别分布(170053例)。
- 由两名评价者独立筛选和提取数据,遵循PRISMA指南;采用随机效应Meta分析合并接受治疗的男婴和女婴比例。
主要发现
- 接受ROP治疗的男婴比例较高(55% [95% CI, 0.54%-0.55%]),研究间异质性低(I2=34%;P<.001)。
- 38项研究报告筛查人群性别分布:男性92612例(53%) vs 女性77441例(47%)。
- 筛查男婴与女婴接受治疗的比值无显著差异(合并比值比1.04 [95% CI, 0.91-1.18];P=.67)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Literature and anecdotal evidence suggest a relationship between male sex and retinopathy of prematurity (ROP). It is not known whether a difference, if present, is sex-related pathophysiologic predisposition or sex difference in meeting ROP screening criteria. OBJECTIVE: To evaluate the association of sex with the development of treatment-warranted ROP. DATA SOURCES: PubMed, Embase, and Web of Science databases were searched from 2000 to 2022. The search strategy used keywords including retinopathy of prematurity or ROP or retrolental fibroplasia and treatment or anti-VEGF or bevacizumab or ranibizumab or aflibercept or conbercept or laser or cryotherapy and gender or sex or male or female and medical subject headings terms. STUDY SELECTION: All studies reporting on treatment with anti-vascular endothelial growth factor, laser photocoagulation, and/or cryotherapy for ROP were identified. Studies reporting sex distribution in the treatment group were included in the meta-analysis. Exclusion criteria included case reports, case series of fewer than 10 treated patients, systematic reviews, conference abstracts, letters to the editor, animal studies, and non-English records. DATA EXTRACTION AND SYNTHESIS: Two reviewers independently screened and extracted the data following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The proportions of treated male and female infants were combined using random-effects meta-analysis. MAIN OUTCOMES AND MEASURES: Numbers and percentages of male and female infants treated for ROP. RESULTS: Of 11 368 identified studies, 316 met inclusion criteria, yielding a total of 31 026 treated patients. A higher percentage of male infants were treated for ROP (55% [95% CI, 0.54%-0.55%]), with low heterogeneity between studies (I2 = 34%; P < .001). Thirty-eight studies reported sex distribution in the screened population (170 053 patients; 92 612 [53%] male vs 77 441 [47%] female). There was no significant difference in the odds of receiving treatment between screened male and female infants (pooled odds ratio, 1.04 [95% CI, 0.91-1.18]; P = .67). CONCLUSIONS AND RELEVANCE: More male infants are treated for ROP than female infants. This could be due to a known relative pathophysiological fragility of preterm male infants in addition to a difference in ROP screening rates, with more male infants meeting the criteria than female infants. These findings have implications for future studies and may prompt more careful clinical monitoring of male neonates.
引用
- Hoyek S, Peacker BL, Acaba-Berrocal LA, et al. The Male to Female Ratio in Treatment-Warranted Retinopathy of Prematurity: A Systematic Review and Meta-analysis. JAMA Ophthalmol. 2022. PMID: 36201195. doi:10.1001/jamaophthalmol.2022.3988
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。